Epigenetic control of microglial mitochondrial immunity by KAT7 drives Alzheimer's disease pathogenesis

1. Problem Statement

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques and neurofibrillary tangles, but therapies targeting these proteins have yielded limited clinical success. A central mechanism in AD pathogenesis is chronic neuroinflammation driven by microglia. Recent evidence suggests that cytosolic mitochondrial DNA (mtDNA) acts as a damage-associated molecular pattern (DAMP) that activates the cGAS-STING pathway and the NLRP3 inflammasome, sustaining a pro-inflammatory state. However, the upstream epigenetic mechanisms regulating this mtDNA-initiated inflammatory cascade in microglia remain poorly understood. Specifically, how histone modifications control the transcription of genes essential for mtDNA synthesis and subsequent immune activation in AD is unknown.

2. Methodology

The study employed a multi-faceted approach combining bioinformatics, molecular biology, cell biology, and in vivo animal models:

• Human and Mouse Models:
  • Human: Analysis of post-mortem AD brain tissue (superior frontal gyrus) and primary microglia.
  • Mouse: 5×FAD mice (a robust AD model with five familial mutations) crossed with Cx3cr1-CreER mice to achieve microglia-specific conditional knockout (cKO) of Kat7.
  • Pharmacology: Use of WM-3835, a potent small-molecule inhibitor of KAT7, administered via intracerebroventricular (ICV) osmotic pumps in 5×FAD mice.
• Genetic Manipulation:
  • Generation of Kat7 floxed mice using Easi-CRISPR.
  • CRISPR-Cas9 knockout and siRNA knockdown in BV2 microglial cells and primary microglia.
  • Overexpression of wild-type (WT) and catalytically inactive mutants of KAT7 and its target, CMPK2.
• Omics and Epigenomic Profiling:
  • RNA-seq: To identify transcriptomic changes in Kat7 KO vs. WT microglia upon LPS stimulation.
  • CUT&Tag: To map genome-wide H3K14ac (the specific histone mark catalyzed by KAT7) distribution.
  • Integrative Analysis: Overlapping RNA-seq and CUT&Tag data to identify direct transcriptional targets.
• Functional Assays:
  • mtDNA Synthesis: EdU labeling to track newly synthesized mtDNA.
  • mtDNA Release: qPCR of cytosolic fractions to measure cytosolic mtDNA levels.
  • Signaling: Western blotting and immunofluorescence for cGAS-STING pathway markers (p-TBK1, p-IRF3) and inflammatory cytokines (IL-6, IL-1β, iNOS).
  • Behavioral & Electrophysiological: Morris water maze (spatial memory), field potential recordings for Long-Term Potentiation (LTP), and Thioflavin S staining for Aβ plaque burden.

3. Key Contributions

• Identification of KAT7: The study identifies KAT7 (HBO1), a histone acetyltransferase, as a critical epigenetic regulator of microglial innate immunity in AD.
• Discovery of the KAT7-CMPK2 Axis: The authors establish CMPK2 (Cytidine/uridine monophosphate kinase 2) as a direct transcriptional target of KAT7.
• Mechanistic Link: They elucidate a novel pathway where KAT7-mediated histone acetylation drives mtDNA synthesis, leading to cytosolic mtDNA leakage, cGAS-STING activation, and chronic neuroinflammation.
• Therapeutic Validation: The study provides preclinical proof-of-concept that both genetic deletion and pharmacological inhibition of KAT7 can reverse AD pathology.

4. Key Results

A. KAT7 is Upregulated in AD Microglia

• Expression: Kat7 and its scaffold subunits (Jade2, Brpf2) are significantly upregulated in microglia from 5×FAD mice and human AD brains compared to controls.
• Epigenetic Mark: Levels of H3K14ac (the specific mark deposited by KAT7) are markedly elevated in microglia of AD models but not in neurons or astrocytes.

B. KAT7 Drives Inflammation via CMPK2

• Transcriptional Target: Integrative RNA-seq and CUT&Tag analyses identified CMPK2 as a top direct target of KAT7. KAT7 binds to the Cmpk2 promoter, increasing H3K14ac and driving transcription.
• Enzymatic Dependence: The pro-inflammatory effect of KAT7 requires its catalytic activity (HAT function) and is dependent on its interaction with the scaffold protein JADE2.
• Downstream Effects: Loss of KAT7 reduces Cmpk2 expression, which in turn impairs mtDNA replication (measured by EdU incorporation).

C. Disruption of the mtDNA-Immune Axis

• Mechanism: KAT7 promotes CMPK2-dependent mtDNA synthesis. In the absence of KAT7, mtDNA synthesis is reduced, preventing the release of mtDNA into the cytosol.
• Signaling Consequence: Reduced cytosolic mtDNA leads to decreased activation of the cGAS-STING pathway (lower p-TBK1 and p-IRF3) and the NLRP3 inflammasome, resulting in suppressed production of IL-1β and IL-6.
• Rescue: Overexpression of WT CMPK2, but not a catalytically inactive mutant, rescues mtDNA synthesis and immune signaling in Kat7-deficient cells.

D. In Vivo Efficacy in 5×FAD Mice

• Microglia-specific Deletion: Kat7 cKO in 5×FAD mice resulted in:
  • Reduced cytosolic mtDNA and dampened cGAS-STING/NLRP3 signaling.
  • Decreased microglial activation (Iba1+ cells) and neuroinflammation.
  • Reduced Aβ plaque burden in the cortex and hippocampus.
  • Restored synaptic plasticity (rescued LTP deficits).
  • Improved cognitive function (enhanced spatial learning and memory in the Morris water maze).
• Pharmacological Inhibition: Chronic ICV infusion of WM-3835 in 5×FAD mice recapitulated the genetic findings: reduced H3K14ac, suppressed neuroinflammation, lowered Aβ burden, and improved cognition.
• Safety: Excitatory neuron-specific Kat7 deletion in adult mice did not impair synaptic transmission or plasticity, suggesting KAT7 inhibition is well-tolerated in mature neurons.

5. Significance

• Novel Pathogenic Mechanism: This study uncovers an epigenetic-mitochondrial axis (KAT7 → H3K14ac → CMPK2 → mtDNA synthesis → cGAS-STING) that sustains chronic neuroinflammation in AD. It links epigenetic dysregulation directly to metabolic reprogramming (mtDNA synthesis) and innate immunity.
• Therapeutic Target: KAT7 is identified as a promising therapeutic target. Unlike broad anti-inflammatory approaches, targeting KAT7 specifically disrupts the mtDNA-driven inflammatory loop in microglia.
• Translational Potential: The efficacy of the small-molecule inhibitor WM-3835 in a preclinical AD model suggests that KAT7 inhibition could be a viable strategy for treating AD and potentially other neurodegenerative diseases characterized by chronic neuroinflammation.
• Cell-Type Specificity: The findings highlight the importance of cell-type-specific epigenetic regulation, showing that KAT7's pathogenic role is specific to microglia in the context of AD, while being dispensable for mature neuronal function.

In conclusion, the paper establishes KAT7 as a master regulator linking chromatin remodeling to mitochondrial immunity in microglia, offering a new mechanistic understanding of AD pathogenesis and a potential disease-modifying therapeutic avenue.